Loading…

Enhanced Hypoprothrombinemia with Warfarin Due to Azithromycin

OBJECTIVE: To report a case of probable azithromycin—warfarin drug interaction with enhanced hypoprothrombinemic effect of warfarin. CASE SUMMARY: An 83-year-old African American man stabilized on warfarin therapy (10 mg on Wednesdays, 7.5 mg on other days) developed a prolonged prothrombin time one...

Full description

Saved in:
Bibliographic Details
Published in:The Annals of pharmacotherapy 2004-06, Vol.38 (6), p.982-985
Main Authors: Rao, Krishnamoorthy B, Pallaki, Muralidhar, Tolbert, Sandra R, Hornick, Thomas R
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c342t-b60fe72cf89d94dd3249c51e702929197cc0b870e1d3fac31a6f361739b7b7813
cites cdi_FETCH-LOGICAL-c342t-b60fe72cf89d94dd3249c51e702929197cc0b870e1d3fac31a6f361739b7b7813
container_end_page 985
container_issue 6
container_start_page 982
container_title The Annals of pharmacotherapy
container_volume 38
creator Rao, Krishnamoorthy B
Pallaki, Muralidhar
Tolbert, Sandra R
Hornick, Thomas R
description OBJECTIVE: To report a case of probable azithromycin—warfarin drug interaction with enhanced hypoprothrombinemic effect of warfarin. CASE SUMMARY: An 83-year-old African American man stabilized on warfarin therapy (10 mg on Wednesdays, 7.5 mg on other days) developed a prolonged prothrombin time one day after starting azithromycin 500 mg. The elevated prothrombin time normalized 3 days after azithromycin was discontinued. After the initial increase in the international normalized ratio, the absence of any significant confounding factors affecting the anticoagulant effect of warfarin in our patient and the numerous reports of such interactions indicate that an interaction between azithromycin and warfarin may have been responsible for the elevated prothrombin time seen in this patient. An objective causality assessment revealed that the adverse event was probably related to the combination of these drugs. DISCUSSION: Azithromycin, unlike erythromycin and clarithromycin, is not known to inhibit the cytochrome P450 enzyme system and is presumed to be the macrolide of choice in patients already on warfarin. However, previously reported cases of azithromycin—warfarin interactions support the possibility that azithromycin does interact with warfarin, although the exact mechanism is not understood. CONCLUSIONS: Azithromycin may interact with warfarin and enhance its hypoprothrombinemic effects. This effect may be delayed for 4–8 days after a course of azithromycin has been completed. Periodic monitoring of the prothrombin time is recommended when using azithromycin in patients taking warfarin.
doi_str_mv 10.1345/aph.1D489
format article
fullrecord <record><control><sourceid>sage_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1345_aph_1D489</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1345_aph.1D489</sage_id><sourcerecordid>10.1345_aph.1D489</sourcerecordid><originalsourceid>FETCH-LOGICAL-c342t-b60fe72cf89d94dd3249c51e702929197cc0b870e1d3fac31a6f361739b7b7813</originalsourceid><addsrcrecordid>eNpt0M9LwzAUB_AgipvTg_-A9KLgofMlaZvkIoxtOmHgRfEY0jRZM9YfpB1l_vXWdeDF03uHD1_e-yJ0i2GKaRQ_qTqf4kXExRka4zgiYUIYnPc7JBAC4TBCV02zBQCBibhEIxwDjxIej9HzssxVqU0WrA51VfuqzX1VpK40hVNB59o8-FLeKu_KYLE3QVsFs293RAftymt0YdWuMTenOUGfL8uP-Spcv7--zWfrUNOItGGagDWMaMtFJqIsoyQSOsaGARFEYMG0hpQzMDijVmmKVWJpghkVKUsZx3SCHodc7aum8cbK2rtC-YPEIH87kH0H8thBb-8GW-_TwmR_8vR0Dx4G0KiNkdtq78v-9n-T7geYu03eOW9kU6jdrs_Fsus6ymUiBSf0B1XccKA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Enhanced Hypoprothrombinemia with Warfarin Due to Azithromycin</title><source>SAGE:Jisc Collections:SAGE Journals Read and Publish 2023-2024:2025 extension (reading list)</source><creator>Rao, Krishnamoorthy B ; Pallaki, Muralidhar ; Tolbert, Sandra R ; Hornick, Thomas R</creator><creatorcontrib>Rao, Krishnamoorthy B ; Pallaki, Muralidhar ; Tolbert, Sandra R ; Hornick, Thomas R</creatorcontrib><description>OBJECTIVE: To report a case of probable azithromycin—warfarin drug interaction with enhanced hypoprothrombinemic effect of warfarin. CASE SUMMARY: An 83-year-old African American man stabilized on warfarin therapy (10 mg on Wednesdays, 7.5 mg on other days) developed a prolonged prothrombin time one day after starting azithromycin 500 mg. The elevated prothrombin time normalized 3 days after azithromycin was discontinued. After the initial increase in the international normalized ratio, the absence of any significant confounding factors affecting the anticoagulant effect of warfarin in our patient and the numerous reports of such interactions indicate that an interaction between azithromycin and warfarin may have been responsible for the elevated prothrombin time seen in this patient. An objective causality assessment revealed that the adverse event was probably related to the combination of these drugs. DISCUSSION: Azithromycin, unlike erythromycin and clarithromycin, is not known to inhibit the cytochrome P450 enzyme system and is presumed to be the macrolide of choice in patients already on warfarin. However, previously reported cases of azithromycin—warfarin interactions support the possibility that azithromycin does interact with warfarin, although the exact mechanism is not understood. CONCLUSIONS: Azithromycin may interact with warfarin and enhance its hypoprothrombinemic effects. This effect may be delayed for 4–8 days after a course of azithromycin has been completed. Periodic monitoring of the prothrombin time is recommended when using azithromycin in patients taking warfarin.</description><identifier>ISSN: 1060-0280</identifier><identifier>EISSN: 1542-6270</identifier><identifier>DOI: 10.1345/aph.1D489</identifier><identifier>PMID: 15084685</identifier><language>eng</language><publisher>Los Angeles, CA: Harvey Whitney Books</publisher><subject>Aged ; Aged, 80 and over ; Anti-Bacterial Agents - adverse effects ; Anticoagulants - adverse effects ; Azithromycin - adverse effects ; Drug Interactions ; Humans ; Hypoprothrombinemias - chemically induced ; Male ; Warfarin - adverse effects</subject><ispartof>The Annals of pharmacotherapy, 2004-06, Vol.38 (6), p.982-985</ispartof><rights>2004 SAGE Publications</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c342t-b60fe72cf89d94dd3249c51e702929197cc0b870e1d3fac31a6f361739b7b7813</citedby><cites>FETCH-LOGICAL-c342t-b60fe72cf89d94dd3249c51e702929197cc0b870e1d3fac31a6f361739b7b7813</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15084685$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rao, Krishnamoorthy B</creatorcontrib><creatorcontrib>Pallaki, Muralidhar</creatorcontrib><creatorcontrib>Tolbert, Sandra R</creatorcontrib><creatorcontrib>Hornick, Thomas R</creatorcontrib><title>Enhanced Hypoprothrombinemia with Warfarin Due to Azithromycin</title><title>The Annals of pharmacotherapy</title><addtitle>Ann Pharmacother</addtitle><description>OBJECTIVE: To report a case of probable azithromycin—warfarin drug interaction with enhanced hypoprothrombinemic effect of warfarin. CASE SUMMARY: An 83-year-old African American man stabilized on warfarin therapy (10 mg on Wednesdays, 7.5 mg on other days) developed a prolonged prothrombin time one day after starting azithromycin 500 mg. The elevated prothrombin time normalized 3 days after azithromycin was discontinued. After the initial increase in the international normalized ratio, the absence of any significant confounding factors affecting the anticoagulant effect of warfarin in our patient and the numerous reports of such interactions indicate that an interaction between azithromycin and warfarin may have been responsible for the elevated prothrombin time seen in this patient. An objective causality assessment revealed that the adverse event was probably related to the combination of these drugs. DISCUSSION: Azithromycin, unlike erythromycin and clarithromycin, is not known to inhibit the cytochrome P450 enzyme system and is presumed to be the macrolide of choice in patients already on warfarin. However, previously reported cases of azithromycin—warfarin interactions support the possibility that azithromycin does interact with warfarin, although the exact mechanism is not understood. CONCLUSIONS: Azithromycin may interact with warfarin and enhance its hypoprothrombinemic effects. This effect may be delayed for 4–8 days after a course of azithromycin has been completed. Periodic monitoring of the prothrombin time is recommended when using azithromycin in patients taking warfarin.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Anti-Bacterial Agents - adverse effects</subject><subject>Anticoagulants - adverse effects</subject><subject>Azithromycin - adverse effects</subject><subject>Drug Interactions</subject><subject>Humans</subject><subject>Hypoprothrombinemias - chemically induced</subject><subject>Male</subject><subject>Warfarin - adverse effects</subject><issn>1060-0280</issn><issn>1542-6270</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><recordid>eNpt0M9LwzAUB_AgipvTg_-A9KLgofMlaZvkIoxtOmHgRfEY0jRZM9YfpB1l_vXWdeDF03uHD1_e-yJ0i2GKaRQ_qTqf4kXExRka4zgiYUIYnPc7JBAC4TBCV02zBQCBibhEIxwDjxIej9HzssxVqU0WrA51VfuqzX1VpK40hVNB59o8-FLeKu_KYLE3QVsFs293RAftymt0YdWuMTenOUGfL8uP-Spcv7--zWfrUNOItGGagDWMaMtFJqIsoyQSOsaGARFEYMG0hpQzMDijVmmKVWJpghkVKUsZx3SCHodc7aum8cbK2rtC-YPEIH87kH0H8thBb-8GW-_TwmR_8vR0Dx4G0KiNkdtq78v-9n-T7geYu03eOW9kU6jdrs_Fsus6ymUiBSf0B1XccKA</recordid><startdate>20040601</startdate><enddate>20040601</enddate><creator>Rao, Krishnamoorthy B</creator><creator>Pallaki, Muralidhar</creator><creator>Tolbert, Sandra R</creator><creator>Hornick, Thomas R</creator><general>Harvey Whitney Books</general><general>SAGE Publications</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20040601</creationdate><title>Enhanced Hypoprothrombinemia with Warfarin Due to Azithromycin</title><author>Rao, Krishnamoorthy B ; Pallaki, Muralidhar ; Tolbert, Sandra R ; Hornick, Thomas R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c342t-b60fe72cf89d94dd3249c51e702929197cc0b870e1d3fac31a6f361739b7b7813</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Anti-Bacterial Agents - adverse effects</topic><topic>Anticoagulants - adverse effects</topic><topic>Azithromycin - adverse effects</topic><topic>Drug Interactions</topic><topic>Humans</topic><topic>Hypoprothrombinemias - chemically induced</topic><topic>Male</topic><topic>Warfarin - adverse effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rao, Krishnamoorthy B</creatorcontrib><creatorcontrib>Pallaki, Muralidhar</creatorcontrib><creatorcontrib>Tolbert, Sandra R</creatorcontrib><creatorcontrib>Hornick, Thomas R</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>The Annals of pharmacotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rao, Krishnamoorthy B</au><au>Pallaki, Muralidhar</au><au>Tolbert, Sandra R</au><au>Hornick, Thomas R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Enhanced Hypoprothrombinemia with Warfarin Due to Azithromycin</atitle><jtitle>The Annals of pharmacotherapy</jtitle><addtitle>Ann Pharmacother</addtitle><date>2004-06-01</date><risdate>2004</risdate><volume>38</volume><issue>6</issue><spage>982</spage><epage>985</epage><pages>982-985</pages><issn>1060-0280</issn><eissn>1542-6270</eissn><abstract>OBJECTIVE: To report a case of probable azithromycin—warfarin drug interaction with enhanced hypoprothrombinemic effect of warfarin. CASE SUMMARY: An 83-year-old African American man stabilized on warfarin therapy (10 mg on Wednesdays, 7.5 mg on other days) developed a prolonged prothrombin time one day after starting azithromycin 500 mg. The elevated prothrombin time normalized 3 days after azithromycin was discontinued. After the initial increase in the international normalized ratio, the absence of any significant confounding factors affecting the anticoagulant effect of warfarin in our patient and the numerous reports of such interactions indicate that an interaction between azithromycin and warfarin may have been responsible for the elevated prothrombin time seen in this patient. An objective causality assessment revealed that the adverse event was probably related to the combination of these drugs. DISCUSSION: Azithromycin, unlike erythromycin and clarithromycin, is not known to inhibit the cytochrome P450 enzyme system and is presumed to be the macrolide of choice in patients already on warfarin. However, previously reported cases of azithromycin—warfarin interactions support the possibility that azithromycin does interact with warfarin, although the exact mechanism is not understood. CONCLUSIONS: Azithromycin may interact with warfarin and enhance its hypoprothrombinemic effects. This effect may be delayed for 4–8 days after a course of azithromycin has been completed. Periodic monitoring of the prothrombin time is recommended when using azithromycin in patients taking warfarin.</abstract><cop>Los Angeles, CA</cop><pub>Harvey Whitney Books</pub><pmid>15084685</pmid><doi>10.1345/aph.1D489</doi><tpages>4</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1060-0280
ispartof The Annals of pharmacotherapy, 2004-06, Vol.38 (6), p.982-985
issn 1060-0280
1542-6270
language eng
recordid cdi_crossref_primary_10_1345_aph_1D489
source SAGE:Jisc Collections:SAGE Journals Read and Publish 2023-2024:2025 extension (reading list)
subjects Aged
Aged, 80 and over
Anti-Bacterial Agents - adverse effects
Anticoagulants - adverse effects
Azithromycin - adverse effects
Drug Interactions
Humans
Hypoprothrombinemias - chemically induced
Male
Warfarin - adverse effects
title Enhanced Hypoprothrombinemia with Warfarin Due to Azithromycin
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T23%3A55%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-sage_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Enhanced%20Hypoprothrombinemia%20with%20Warfarin%20Due%20to%20Azithromycin&rft.jtitle=The%20Annals%20of%20pharmacotherapy&rft.au=Rao,%20Krishnamoorthy%20B&rft.date=2004-06-01&rft.volume=38&rft.issue=6&rft.spage=982&rft.epage=985&rft.pages=982-985&rft.issn=1060-0280&rft.eissn=1542-6270&rft_id=info:doi/10.1345/aph.1D489&rft_dat=%3Csage_cross%3E10.1345_aph.1D489%3C/sage_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c342t-b60fe72cf89d94dd3249c51e702929197cc0b870e1d3fac31a6f361739b7b7813%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/15084685&rft_sage_id=10.1345_aph.1D489&rfr_iscdi=true